Status:
TERMINATED
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Conditions:
Spinal Muscular Atrophy Type 3
Eligibility:
All Genders
6-50 years
Phase:
PHASE2
Brief Summary
A long term safety study of amifampridine phosphate in patients with spinal muscular atrophy (SMA) Type 3.
Detailed Description
This open-label outpatient extension study was designed to evaluate the long-term safety and tolerability of amifampridine in patients diagnosed with SMA Type 3. In addition, the evaluation of the eff...
Eligibility Criteria
Inclusion
- Individuals eligible to participate in this study must meet all the following inclusion criteria:
- Participated in the SMA-001 study
- Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.
- Female patients of childbearing potential must have a negative pregnancy test (urine human chorionic gonadotropin \[HCG\] at the end of SMA-001 study); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.
- Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.
Exclusion
- Individuals who met any of the exclusion criteria in the original protocol or those listed below are not eligible to participate in the study:
- Epilepsy and currently on medication.
- Uncontrolled asthma.
- Concomitant use with sultopride.
- Concomitant use with medicinal products with a narrow therapeutic window.
- Concomitant use with medicinal products with a known to cause QTc prolongation.
- Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator.
- Subjects with congenital QT syndromes.
- Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.
- Intolerable amifampridine-related side effects
- Treatment with an investigational drug (other than amifampridine) or device while participating in this study.
- Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.
- History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).
Key Trial Info
Start Date :
March 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2021
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03819660
Start Date
March 7 2019
End Date
September 13 2021
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurological Institute Carlo Besta
Milan, Lombardy, Italy, 20133